Ownership and insider activity for Halozyme Therapeutics, Inc. (HALO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Price
| Price | $108.44 |
| Market Cap | $12.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | Torley Helen | M-Exempt | 20,000 | $368K |
| 2026-09-09 | Torley Helen | S-Sale | 13,304 | $1.4M |
| 2026-09-10 | Torley Helen | S-Sale | 14,588 | $1.6M |
| 2026-09-11 | Torley Helen | S-Sale | 15,492 | $1.7M |
| 2026-09-09 | Torley Helen | S-Sale | 6,596 | $711K |
| 2026-09-10 | Torley Helen | S-Sale | 5,412 | $582K |
| 2026-09-09 | Torley Helen | S-Sale | 100 | $11K |
| 2026-09-11 | Torley Helen | S-Sale | 4,508 | $485K |
| 2026-09-09 | Torley Helen | M-Exempt | 20,000 | $368K |
| 2026-09-10 | Torley Helen | M-Exempt | 20,000 | $368K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.8M | $168.7M | $57.9M | $120.2M | $147.7M | $118.7M | $234.2M | $118.4M | $115.8M | $133.8M |
| Short-term Investments | $138.2M | $300.5M | $296.6M | $301.1M | $220.3M | $622.2M | $128.6M | $217.6M | $480.2M | $9.0M |
| Receivables | $15.7M | $22.1M | $30.0M | $59.4M | $97.7M | $91.0M | $231.1M | $234.2M | $308.5M | $441.3M |
| Inventory | $14.6M | $5.1M | $22.6M | $29.4M | $60.7M | $53.9M | $100.1M | $127.6M | $141.9M | $176.5M |
| Total Current Assets | $256.5M | $510.4M | $427.8M | $543.4M | $554.8M | $926.3M | $739.0M | $746.4M | $1.09B | $825.2M |
| Property, Plant & Equipment | $4.3M | $3.5M | $7.5M | $10.9M | $10.6M | $8.8M | $75.6M | $74.9M | $75.0M | $82.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | $409.0M | $416.8M | $416.8M | $580.4M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $546.7M | $472.9M | $401.8M | $981.5M |
| Total Assets | $261.5M | $519.9M | $440.2M | $565.9M | $579.9M | $1.10B | $1.84B | $1.73B | $2.06B | $2.53B |
| Accounts Payable | $3.6M | $7.9M | $4.1M | $6.4M | $1.9M | $1.5M | $17.7M | $11.8M | $10.2M | $20.9M |
| Short-term Debt | $17.4M | $77.2M | $91.5M | $19.5M | $397.2M | $89.4M | $13.3M | 0 | 0 | 0 |
| Total Current Liabilities | $54.6M | $131.3M | $149.4M | $85.6M | $421.4M | $117.1M | $130.8M | $112.5M | $139.1M | $177.1M |
| Long-term Debt | $199.2M | $125.1M | $34.9M | $383.0M | 0 | $787.3M | $1.49B | $1.50B | $1.51B | $2.14B |
| Total Liabilities | $294.0M | $311.6M | $191.4M | $474.1M | $428.9M | $907.5M | $1.67B | $1.65B | $1.70B | $2.48B |
| Retained Earnings | -$585.3M | -$522.4M | -$531.4M | -$603.7M | -$474.6M | -$58.9M | $143.2M | $90.5M | $359.9M | $54.8M |
| Total Equity | -$32.5M | $208.4M | $248.9M | $91.8M | $151.0M | $197.0M | $169.8M | $83.8M | $363.8M | $48.8M |
| Total Debt | $216.6M | $202.4M | $126.4M | $402.6M | $397.2M | $876.7M | $1.51B | $1.50B | $1.51B | $2.14B |
| Net Debt | $11.6M | -$266.9M | -$228.1M | -$18.7M | $29.2M | $135.8M | $1.14B | $1.16B | $909.7M | $2.00B |
| Working Capital | $201.9M | $379.0M | $278.5M | $457.8M | $133.4M | $809.1M | $608.2M | $633.9M | $946.2M | $648.1M |
Financial Health
| Debt / Equity | 14.95 |
| Current Ratio | 2.71 |
Profitability
| Gross Margin | 78.18% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks